MAP announces progress in FDA application for Levadex

01/11/2010 | Reuters

The FDA concluded that MAP Pharmaceuticals does not need to conduct a second clinical trial to support its regulatory application for migraine drug Levadex. Analysts said the decision will help the drugmaker find a development partner for the orally inhaled treatment, which met all goals of a late-stage trial in May.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC